Advances in our understanding of the role of PARP1 in DNA repair have expanded the clinical application of PARP inhibitors in various diseases, especially cancers, as tumor cells are highly sensitive to PARP inhibition because of DNA repair defects (Curtin and Szabo, 2020). The gene discussed is PARP1; the disease is cancer.